首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF8B |
| Uniprot No | P55075-3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-215aa |
| 氨基酸序列 | QVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQVLANKR INAMAEDGDPFAKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIAKSNG KGKDCVFTEIVLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQHQREV HFMKRLPRGHHTTEQSLRFEFLNYPPFTRSLRGSQRTWAPEPR |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGF8B重组蛋白的3篇参考文献示例：
---
1. **文献名称**：*FGF8 isoforms activate receptor splice variants that signal through distinct pathways*
**作者**：Heikinheimo, M., et al.
**摘要**：该研究通过重组FGF8B蛋白处理细胞，揭示了其选择性激活FGFR受体亚型的能力，并证明不同FGF8异构体通过特定信号通路(如MAPK/ERK)调控胚胎发育过程中的细胞增殖与分化。
2. **文献名称**：*Recombinant FGF8b induces neural crest cell differentiation in vitro*
**作者**：Sato, T., et al.
**摘要**：作者利用重组FGF8B蛋白处理神经嵴前体细胞，发现其显著促进神经元和胶质细胞的分化，表明FGF8B在神经发育中通过调控Wnt和BMP通路发挥关键作用。
3. **文献名称**：*FGF8b overexpression enhances tumorigenicity and metastasis in ovarian cancer via autocrine signaling*
**作者**：Ozaki, K., et al.
**摘要**：研究通过体外实验证实，重组FGF8B蛋白能够激活卵巢癌细胞内的FGFR1受体，促进细胞迁移和侵袭，提示其在肿瘤进展中的潜在治疗靶点价值。
---
注：上述文献为示例性质，实际引用时需核实具体文献来源及细节。建议通过PubMed、Web of Science等平台以“FGF8B recombinant protein”为关键词检索最新研究。
Fibroblast Growth Factor 8B (FGF8B) is a splice variant of the FGF8 gene, belonging to the fibroblast growth factor family, which regulates critical biological processes such as embryonic development, cell proliferation, and tissue repair. FGF8B, specifically, plays a pivotal role in early embryogenesis, including limb formation, neural patterning, and organogenesis. Its expression is tightly regulated, with activity mediated through binding to FGF receptors (FGFRs) and heparan sulfate proteoglycans, activating downstream signaling pathways like MAPK and PI3K-AKT.
Structurally, FGF8B differs from other isoforms (e.g., FGF8A) by its extended N-terminal region, which enhances receptor-binding specificity and stability. Recombinant FGF8B protein is engineered using biotechnological platforms (e.g., bacterial or mammalian expression systems) to ensure proper post-translational modifications, yielding a bioactive product for research and therapeutic applications.
In research, recombinant FGF8B is widely used to study developmental biology, disease mechanisms (e.g., cancer metastasis, neurodevelopmental disorders), and regenerative medicine. Its dysregulation is linked to pathologies such as breast cancer, Parkinson’s disease, and craniofacial abnormalities. Additionally, it serves as a tool for in vitro stem cell differentiation and tissue engineering. Despite its potential, challenges remain in optimizing delivery methods and minimizing off-target effects due to its pleiotropic signaling roles. Current studies focus on elucidating its context-dependent functions and exploring clinical applications in targeted therapies.
×
